The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells by Shapira, Ma'anit et al.
Open Access
Available online http://breast-cancer-research.com/content/8/4/R46
Page 1 of 9
(page number not for citation purposes)
Vol 8 No 4 Research article
The mTOR inhibitor rapamycin down-regulates the expression of 
the ubiquitin ligase subunit Skp2 in breast cancer cells
Ma'anit Shapira1,2, Eli Kakiashvili3, Tzur Rosenberg2 and Dan D Hershko1,2,4
1Department of Surgery A, Rambam Medical Center, Haifa 31096, Israel
2Technion – Israel Institute of Technology, Haifa 31096, Israel
3Department of Surgery B, Rambam Medical Center, Haifa 31096, Israel
4Breast Health Institute, Rambam Medical Center, Haifa 31096, Israel
Corresponding author: Dan D Hershko, d_hershko@rambam.health.gov.il
Received: 28 Apr 2006 Revisions requested: 25 May 2006 Revisions received: 21 Jun 2006 Accepted: 13 Jul 2006 Published: 19 Jul 2006
Breast Cancer Research 2006, 8:R46 (doi:10.1186/bcr1533)
This article is online at: http://breast-cancer-research.com/content/8/4/R46
© 2006 Shapira et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Loss of the cyclin-dependent kinase inhibitor p27
is associated with poor prognosis in breast cancer. The
decrease in p27 levels is mainly the result of enhanced
proteasome-dependent degradation mediated by its specific
ubiquitin ligase subunit S phase kinase protein 2 (Skp2). The
mammalian target of rapamycin (mTOR) is a downstream
mediator in the phosphoinositol 3' kinase (PI3K)/Akt pathway
that down-regulates p27 levels in breast cancer. Rapamycin
was found to stabilize p27 levels in breast cancer, but whether
this effect is mediated through changes in Skp2 expression is
unknown.
Methods The expression of Skp2 mRNA and protein levels
were examined in rapamycin-treated breast cancer cell lines.
The effect of rapamycin on the degradation rate of Skp2
expression was examined in cycloheximide-treated cells and in
relationship to the anaphase promoting complex/Cdh1 (APC\C)
inhibitor Emi1.
Results Rapamycin significantly decreased Skp2 mRNA and
protein levels in a dose and time-dependent fashion, depending
on the sensitivity of the cell line to rapamycin. The decrease in
Skp2 levels in the different cell lines was followed by cell growth
arrest at G1. In addition, rapamycin enhanced the degradation
rate of Skp2 and down-regulated the expression of the APC\C
inhibitor Emi1.
Conclusion These results suggest that Skp2, an important
oncogene in the development and progression of breast cancer,
may be a novel target for rapamycin treatment.
Introduction
Loss of p27, an inhibitor of cyclin-dependent kinases (Cdks),
commonly occurs in malignant diseases and may have a pro-
found impact on the rate of tumor progression and patients'
clinical outcome (reviewed in Tsihlias and colleagues [1]).
Studies have shown that the decrease in p27 levels in these
cancers is mainly the result of its rapid degradation by the
ubiquitin-proteasome pathway rather than from decreased
protein synthesis or gene mutation [2,3]. The machinery
involved in targeting p27 for degradation is an SCF (Skp1-
Cullin-F-box protein)-type ubiquitin ligase complex that con-
tains S phase kinase protein (Skp)2 as the specific substrate
recognizing subunit [4,5]. SCF complexes belong to a large
family of ubiquitin ligases that contain several constant subu-
nits (called Cullin-1, Skp1 and ROC1) and a variable subunit
known as an F-box protein [6]. Each F-box protein binds a spe-
cific subset of protein substrates and thus promotes their liga-
tion to ubiquitin and subsequent degradation by the
proteasome [7].
Skp2 is an F-box protein that was originally discovered, along
with Skp1, as a protein associated with the S-phase kinase
Cdk2/cyclin A and hence its name. The role of Skp2 as the
main rate limiting regulator for the degradation of p27 has
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been clearly shown in several human cancers, including breast
cancer [8-11]. Moreover, tumors overexpressing Skp2 were
strongly associated with low p27 levels and poor disease-free
and overall survival [9-11]. The exact mechanisms that pro-
mote Skp2 overexpression in these cancers are at present not
well understood. It was suggested that Skp2 acts as an onco-
gene in breast cancer and thus is overexpressed by increased
transcriptional activity [11]. However, more recent in vitro
studies have discovered that Skp2 is also regulated by its rate
of protein degradation, which by itself is mediated by the ubiq-
uitin-proteolytic system [12,13]. These studies have found that
the specific ubiquitin ligase that targets Skp2 for degradation
is the anaphase promoting complex/Cdh1 (APC/C). However,
the role of APC/C activity in the regulation of Skp2 levels in
human cancers is at present unknown.
Some studies have shown that alternative cellular mechanisms
may also be involved in p27 deregulation in cancer. For exam-
ple, constitutive activation of phosphoinositol 3' kinase (PI3K)
and its effector protein kinase B (PKB/Akt) down-regulate p27
nuclear levels by either repressing its transcription through Akt
phosphorylation of forkhead transcription factors or by impair-
ing nuclear import, leading to cytoplasmic accumulation of
p27 [14,15]. Activation of this pathway commonly occurs in
breast cancer and may arise through oncogenic receptor tyro-
sine kinase activation, mutational loss of PTEN (phosphatase
and tensin homologue deleted from chromosome 10), or
through activating mutation of PKB/Akt [16,17]. It can also be
activated by membrane receptors, including the HER family of
growth factor receptors, the insulin-like growth factor recep-
tors or by estrogen receptors [18-20]. Some studies have sug-
gested that PI3K/Akt activation may also affect the rate of p27
proteolysis in some human cancers [21-23]. In multiple mye-
loma, for example, inhibition of the PI3K/Akt pathway by
LY294002 resulted in p27 accumulation, which, in turn, was
associated with a decrease in Skp2 levels [23]. However, the
mechanisms that down-regulate Skp2 expression by inhibition
of this pathway in multiple myeloma or in any other cancer are
at present unknown.
The mammalian target of rapamycin (mTOR; also known as
FRAP, RAFT1 and RAPT1) is a downstream effector of the
PI3/Akt pathway that has recently received great attention as
a potential novel therapeutic modality for the treatment of
breast cancer. Rapamycin and its synthetic analogues target
mTOR by binding to immunophilin FK506 binding protein 12,
thereby inhibiting signals required for cell cycle progression
and cell growth [24,25]. By inhibiting mTOR, it inactivates
both the 40S ribosomal protein (S6K1) and 4E-binding pro-
tein 1 (4E-BP1), which are important for translation of specific
mRNA involved in cell cycle progression, and thus lead to
growth arrest at G1. In clinical trials, treatment with either
rapamycin or its analogue CCI-779 have shown remarkable
anticancer activities in some patients, but others did not
respond [26,27]. Recent studies explored the determinants of
sensitivity of breast cancer cell lines to rapamycin, and discov-
ered that cells that express high levels of activated Akt or
S6K1 were also highly sensitive to rapamycin [28]. It was also
found that in rapamycin-sensitive cells p27 levels were up-reg-
ulated, but whether this was caused by altering Skp2-depend-
ent degradation was not examined.
In the present study, we examined the effects of rapamycin on
Skp2 expression in breast cancer lines and the regulatory
mechanisms that determine its cellular abundance. Our results
suggest that rapamycin down-regulates Skp2 expression in
cultured breast cancer cell lines by interfering with gene tran-
scription as well as by increasing its rate of protein degrada-
tion.
Materials and methods
Cell cultures and transfections
Human breast cancer cell lines T47D and MDA-MB-231 were
provided by Dr H Degani (Weizmann Institute of Science,
Rehovot, Israel). Because Skp2 levels change during the cell
cycle (being normally highest in the S-phase and lowest in G1
phase) we cultured the cells in different media under condi-
tions of similar proliferation rates in both cell lines. MDA-MB-
231 cells were grown in RPMI medium (Biological Industries,
Beth Ha'emek, Israel) supplemented with 10% fetal calf
serum, 100 Units penicillin and 100 μg streptomycin per ml
and 1 mM sodium pyruvate. T47D cells were cultured in a sim-
ilar medium that also contained 10 μg/ml insulin. Both cell
lines were cultured at 37°C in 5% CO2. Under these condi-
tions, the proliferation rate of all cell lines was similar (21 to 22
h doubling time). For transfection studies, T47D cells were
seeded at a density of 5 × 105 cells per 60 mm petri dish and
transfected with either pcDNAIII empty vector or Flag-tagged
Skp2 in pcDNAIII vector (2 μg) using FuGENE 6 reagent
(Roche Applied Science, Mannheim, Germany).
Proliferation assays
Cells were seeded in 24-well plates at a concentration of 1 ×
104 cells/per well for 24 h and then treated with different con-
centrations of rapamycin or DMSO. Cells were then detached
from the wells at different time points (12 to 72 h) by trypsin
and counted by hemocytometry.
Protein extract preparation
Cells were grown in 10 cm dishes until 80% confluence was
reached before use. They were harvested into ice-cold PBS
and pelleted by centrifugation (200 g for 3 minutes). Cells
were then suspended in one packed-cell volume of lysis buffer
containing 50 mM Tris-HCl pH 7.6, 250 mM NaCl, 10 mM
EDTA, 0.5% Nonidet P-40, 50 mM NaF, 10 μg/ml leupeptin,
10 μg/ml chymostatin, 10 μg/ml pepstatin, 2 mM N-ethylmale-
imide, 1 mM Phenylmethanesulfonyl fluoride (PMSF) and
1:100 protease inhibitor cocktail (Sigma Aldrich, Rehovot,
Israel), incubated on ice for 30 minutes and centrifuged again
at 20,000 g for 15 minutes. Protein concentrations wereAvailable online http://breast-cancer-research.com/content/8/4/R46
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determined by the Bradford assay (Bio-Rad Laboratories, Her-
cules, CA, USA) using bovine albumin as the standard.
Western blot analysis
Aliquots containing 30 μg protein were resolved by electro-
phoresis on a 12% SDS-polyacrylamide gel and transferred to
nitrocellulose membranes. The membranes were probed with
mouse monoclonal antibody directed against either Skp2
(Zymed Inc., San Francisco, CA, USA) at 1:500, p27 (Trans-
duction Laboratories, Lexington, KY, USA) at 1:1000 or the
polyclonal rabbit early mitotic inhibitor 1 (Emi1; gift of Dr
Pagano, New York University, NY, USA) at 1:250. The same
nitrocellulose membranes were also probed with a mouse
monoclonal antibody directed against Skp1 (1:1000 dilution;
Transduction Laboratories). Because levels of Skp1 do not
change in the cell cycle, this protein served as an internal con-
trol for normalization with respect to the loading of cellular pro-
tein. To detect phosphorylated proteins in the mTOR pathway
we used rabbit polyclonal antibodies against phospho-4E-
BP1 (Thr37/46) or phospho-p70 S6 kinase (Thr389) (Cell
Signaling Technology Inc., Beverly, MA, USA) diluted at
1:1000. For the latter antibodies, bovine serum albumin
instead of dry milk was used in blocking buffer and antibody
solutions. After washing with Tris Buffer Saline with 0.1%
Tween 20 (TBST), the immunoreactive proteins were visual-
ized with HRP-conjugated secondary antibody (Pierce Bio-
technology, Rockford, IL, USA) at 1:10,000, and by enhanced
chemiluminescence (SuperSignal West Pico; Pierce Biotech-
nology). All blots were repeated at least twice. Protein levels
were quantified with ImageMaster VSD-CL (Rhenium, Jerusa-
lem, Israel) using Bio Imaging System 303PC software (DNR
Bio Imaging Systems, Jerusalem, Israel). Analyses were done
using TINA 2.1 software (Raytest, Straubenhardt, Germany).
RNA extraction and real-time RT-PCR
Total RNA was extracted by a modification of the acid gua-
nidinium thiocyanate-phenol-chloroform method using Tri-
Reagent solution (Molecular Research Center, Cincinnati,
OH, USA) according to the manufacturer's instructions. Final
pellets were dissolved in 40 μl RNase-free water with 1 u/μl
RNasin (Promega, Medison, WI). RNA quantification was per-
formed using spectrophotometry and samples were diluted to
0.5 μg/μl concentration. The quality of RNA was determined
by loading 2 μg on RNA-agarose gel (1.2%) and fine concen-
tration corrections were made using UVIgelstarMw software
(UVItec, Cambridge, UK). Only intact RNA was used for fur-
ther experiments.
Quantitative real-time reverse-transcription PCR (RT-PCR)
analyses for mRNA were performed using Rotor Gene 2000
real time cycler instrument and software (Corbett, Australia)
with a QuantiTec SYBR Green RT-PCR kit (Qiagen, Valencia,
CA, USA). Phosphoglycerate kinase (PGK), a housekeeping
gene, was chosen as an internal standard to control for varia-
bility in amplification. For each condition, duplicate test tubes
containing 100 ng of total RNA and 400 nM Skp2 or PGK
gene primers in a total volume of 25 μl were used. The primers
used were: Skp2, sense primer GCTGCTAAAGGTCTCT-
GGTGT and antisense primer AGGCTTAGATTC
TGCAACTTG; PGK, sense primer TTTAAGGGTTCCT-
GGCACTG, antisense primer CAGTTTGGAGCTCCT-
GGAAG. These resulted in one product of either 292 or 200
base-pairs (bp) with Tm of 81°C and 83°C for Skp2 and PGK
genes, respectively. Reaction profiles used were 35 cycles of
95°C for 5 s, 60°C for 20 s and 72°C for 15 s, followed by
melting of 72 to 90°C. The number of copies was drawn from
a standard curve of 103 to 107 copies/μl for each gene sepa-
rately, and levels of expression were calculated as the ratio
between Skp2 and PGK copies in each RNA sample.
Fluorescence-activated cell sorting
Cells were treated with rapamycin (20 nM) or DMSO (0.02%)
for 24 h, then trypsinized, resuspended in media and spun
down for 5 minutes at 200 g. Cells were then washed with
PBS, and fixed at a final concentration of 106 to 107 cells/ml in
70% ethanol. Samples were kept at 4°C until staining. Fixed
cells were incubated with 100 μl of RNAse 1 mg/ml for 30
minutes at 37°C, followed by 30 minutes incubation with 1 ml
of 50 μg/ml propidium iodide in PBS. Cells were counted on
a FACSCalibur cell sorter using CellQuest software (Beckton
Dickinson, Mountain View, CA, USA). Cell cycle analysis was
preformed by a commercial DNA analysis package (Modfit LT
2.0, Verity Software House Inc., Topsham, ME, USA), and the
percentages of cells in the G1, S, and G2/M phases of the cell
cycle were determined.
Degradation assays
To assess the degradation rate of Skp2 in rapamycin-treated
and untreated cells, cells were seeded at a concentration of
1.2 × 106 cells per dish, cultured for 24 h and then treated
with rapamycin (20 nM) or DMSO (0.02%) for another 24 h.
Cycloheximide (100 μg/ml) was then added to the medium.
Cells were collected at different time points (1 to 4 h) and pro-
tein extracts were prepared as described above. Skp2 levels
and half-life decay were quantified by immunoblot analyses as
described above.
Results
To examine the dose-effect of rapamycin treatment on cellular
growth rate in different breast carcinoma cell lines, cells were
exposed to different concentrations of rapamycin for 72 h. A
significant decrease in cell growth rate was observed after
exposure to 5 nM of rapamycin in both cell lines and this effect
was maximal at 20 nM in MDA-MB-231 cells and at 100 nM in
T47D cells (Figure 1a). To examine the time-dependence
effect of rapamycin on cell proliferation, cells were treated with
rapamycin (20 nM) for different time periods and the effect on
growth rate was assessed. Following an initial delay, a signifi-
cant inhibitory effect on cell growth became evident at 24 h for
T47D cells and after 48 h for the MDA-MB-231 cells, and thisBreast Cancer Research    Vol 8 No 4    Shapira et al.
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effect was further increased up to 72 h (Figure 1b). The cell
cycle inhibitory effect of rapamycin (20 nM), as determined by
fluorescence-activated cell sorting (FACS) analysis, resulted
in a significant proportion of cells arrested at G1 (83.5% com-
pared to 59% in vehicle treated cells) (Figure 2a). To deter-
mine the inhibitory effect of rapamycin on mTOR function in
these experimental conditions, we examined the inactivation of
its two major downstream signaling components p70S6
kinase (S6K1) and 4E-BP1. Cells were treated with rapamycin
at a concentration of 20 nM for 24 h and subjected to western
blot analysis to determine phospho-S6K1 and phospho-4E-
BP1 protein levels. Levels of the phosphorylated forms of both
proteins were markedly decreased by rapamycin at 12 h in
T47D cells and at 24 h in MDA-MB-231 cells, but this effect
was stronger in both cell lines for S6K1 (Figure 2b). Thus, the
inhibitory effect on cell growth was associated with direct inhi-
bition of the phosphorylation of mTOR target proteins S6K1
and 4E-BP1.
Recent studies have shown that activation of the PI3K/Akt
pathway and its downstream mTOR signaling pathway pro-
mote, at least in part, the proliferation rate of breast cancer by
down-regulating p27 nuclear protein levels. Rapamycin, in
turn, was shown to inhibit this effect and stabilize p27 levels,
but whether this effect results from decreased ubiquitin-medi-
ated degradation is unknown. To examine the effect of rapamy-
cin on the expression of Skp2, we initially tested this effect in
T47D, a breast cancer cell line that showed high sensitivity to
rapamycin in our initial experiments. Cells were treated with
rapamycin at a concentration of 20 nM for different time peri-
ods up to 72 h and subjected to western blot analysis. Treat-
ment with rapamycin significantly decreased Skp2 at 24 h
Figure 1
Effect of rapamycin on cell growth Effect of rapamycin on cell growth. (a) The dose-effect curve of rapamycin on cell growth. The breast cancer cell lines T47D and MDA-MB-231 were 
treated with different concentrations of rapamycin for 72 h and the decrease in growth rate compared to control cells was assessed. (b) Time 
dependence of the effect of rapamycin on cell growth. The breast cancer cell lines T47D (left) and MDA-MB-231 (right) were treated with rapamycin 
(20 nM) for different time periods and the decrease in growth rate compared to control cells was assessed. Results are means ± standard error of 
the mean, with n = 3 for each treatment. *p < 0.05 between the two conditions.Available online http://breast-cancer-research.com/content/8/4/R46
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(Figure 3a), a time point that preceded the initiation of cell pro-
liferation arrest (Figure 1b). To examine whether this associa-
tion was valid in other cell lines, we examined the effect of
rapamycin on cell proliferation and Skp2 expression in MDA-
MB-231, a breast cancer cell line that has shown delayed sen-
sitivity to rapamycin. Because Skp2 levels change during the
cell cycle (being normally highest in the S-phase and lowest in
G1) we cultured the cells in different media conditions until
similar growth rates were reached for the two cell lines. The
effect of rapamycin on Skp2 expression in MDA-MB-231 cells
was evident only after 48 h (Figure 3a), but again, it preceded
the initiation of cell growth inhibition in this cell line (Figure 1b).
Agents that cause a block in G1 can affect cell cycle progres-
sion up to a full cell cycle before any difference in cell number
is apparent, since unaffected cells in S and G2/M phases can
complete a cell cycle and divide before being arrested in G1
in the subsequent cell cycle. We therefore examined the cell
cycle distribution over the first 24 h for T47D cells and at 24
and 48 h for MDA-MB-231 cells (Figure 3b). At 8 h 72% of
T47D cells were arrested in G1, increasing to 80% and 85%
at 16 h and 24 h, respectively. At 24 h only 57% of MDA-MB-
231 cells were arrested in G1 (compared to 50% in untreated
cells), but the percentage of cells arrested in G1 increased to
68% at 48 h. Taken together, these results suggest that the
negative effect of rapamycin on Skp2 expression has an
important role in rapamycin-mediated cell growth arrest.
Recent evidence suggests that Skp2 is encoded by an onco-
gene that may be overexpressed in a large variety of cancers,
including breast cancer. More recently, it was found that Skp2
levels may also be regulated at the post-transcriptional level by
its rate of ubiquitin-mediated degradation, regulated by its
specific ubiquitin ligase APC/C [12]. Thus, it was important to
explore the mechanisms by which rapamycin down-regulates
Skp2 expression in breast cancer. In order to examine whether
the decrease in Skp2 protein levels is due to inhibition of tran-
scriptional activation, we subjected T47D cells to 20 nM
rapamycin for 8 h and measured mRNA levels using real-time
RT-PCR. A significant decrease in Skp2 mRNA levels (28%)
Figure 2
The effect of rapamycin on cell cycle profile and mTOR activation The effect of rapamycin on cell cycle profile and mTOR activation. (a) The effect of rapamycin on cell cycle distribution. T47D cells were treated with 
rapamycin (20 nM) or DMSO (0.02%) for 24 h and subjected to FACS analysis to determine the distribution of the cell cycle. (b) The effect of 
rapamycin on the phosphorylation of the mTOR effectors p-S6K1 and p-4E-BP1. The breast cancer cell lines T47D and MDA-MB-231 were treated 
with rapamycin (20 nM) for different time periods and the phosphorylated forms of the proteins was determined by western blot analysis. Skp1 was 
used as a loading control. Arrows indicate the specific bands.Breast Cancer Research    Vol 8 No 4    Shapira et al.
Page 6 of 9
(page number not for citation purposes)
was measured in rapamycin-treated cells compared to control
cells (Figure 4). No further decrease in Skp2 mRNA levels was
observed at later time points (data not shown). To examine
whether rapamycin affected the degradation rate of Skp2, we
next exposed cells to the protein synthesis inhibitor cyclohex-
imide and measured the decay in Skp2 protein levels. The half-
life of Skp2 in vehicle-treated cells was 4.6 h whereas in
rapamycin-treated cells it was 3.5 h (a decrease of 24%) (Fig-
ure 5a). Previous studies showed that accelerated degrada-
tion of Skp2 may result from the alterations in the expression
of Emi1, an inhibitory protein that binds to APC/C and renders
it inactive [12]. As shown in Figure 5b, Emi1 levels were down-
regulated in rapamycin-treated T47D cells compared to con-
trols. Taken together, these results suggest that rapamycin
leads to an accelerated rate of Skp2 degradation, which may
be associated with increased activation of APC\C. To further
examine whether rapamycin affects Skp2 regulation at the
translational level, we transiently transfected cells with a plas-
mid containing a Skp2 insert; 24 h after the transfections, cells
were treated with rapamycin or a vehicle for 48 h. Skp2 protein
levels were significantly higher in Skp2-transfected cells com-
pared to cells transfected with an empty plasmid (Figure 6).
When treated with rapamycin, the reduction in Skp2 protein
levels was similar in both cells (about 30%), suggesting that
rapamycin may also regulate Skp2 protein levels at the post-
transcriptional level.
Discussion
Recent studies have provided evidence that alterations in the
expression of different cell cycle regulatory proteins may have
a significant impact on the progression and outcome of cancer
in general and in breast cancer in particular. Among these cell
cycle regulatory proteins, the oncogenic role of Skp2 in breast
cancer has been clearly demonstrated [11,29]. Through
mechanisms that are yet not completely understood, Skp2 is
overexpressed in some cancers and is associated with poor
Figure 3
The effect of rapamycin on Skp2 protein levels and cell cycle distribution The effect of rapamycin on Skp2 protein levels and cell cycle distribution. (a) The effect of rapamycin on Skp2 protein levels. The breast cancer cell 
lines T47D and MDA-MB-231 were treated with rapamycin (20 nM) for different time periods and the expression of the protein was determined by 
western blot analysis. Skp1 was used as a loading control. (b) The time-dependent effect of rapamycin on G1 distribution in T47D and MDA-MB-
231 cells. Cells were treated with rapamycin (20 nM) for different time periods and the percentage of cells in G1 was determined by FACS analysis 
using Modfit LT 2.0 software.Available online http://breast-cancer-research.com/content/8/4/R46
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disease free and overall survival. Skp2 is the ubiquitin ligase
subunit that targets p27 for degradation and is the major
determinant of p27 deregulation in cancer. Because of its
important role as an inhibitor of Cdks at G1, down-regulation
of p27 tumor levels allows uncontrolled tumor proliferation.
Recently, other roles for Skp2 were discovered that may effect
cell cycle progression. For example, it was discovered that
Skp2 regulates the rate of degradation of the Cdk inhibitor
p21 and of the forkhead transcription factor FOXO-1, two
other cell cycle regulatory proteins that play important roles in
cancer progression [30,31]. Thus, the identification of novel
therapeutic interventions that may down-regulate the expres-
sion of Skp2 in cancer may potentially lead to a significant
decrease in cancer progression and control of the disease.
Unfortunately, specific drugs that target Skp2 are unavailable
at present and it is, therefore, important to identify commonly
used drugs that have inhibitory effects on Skp2 expression.
The results of the present study show that specific inhibition of
the mTOR pathway by rapamycin may significantly down-reg-
ulate Skp2 levels in rapamycin-sensitive breast cancer cells.
This effect may explain in part the findings of stabilization of
p27 levels and cell-cycle arrest at G1 by rapamycin. These
results are important for several reasons. First, these findings
provide additional insight into the mechanisms of action by
which rapamycin arrests cell growth in breast cancer. Previous
studies have shown that activation of S6K1 and 4E-BP1
enhances the translation of critical mRNAs that are involved in
cell cycle progression and cell proliferation, while inactivation
and dephosphorylation of these proteins inhibits this process,
leading to cell cycle arrest in G1 [24,25]. The increase in p27
levels by rapamycin observed in a number of studies could the-
oretically be secondary to cell cycle arrest at G1. However, our
results show that this effect may result, at least in part, from
direct down-regulation of Skp2 by rapamycin. The decrease in
Skp2 levels preceded that of cell growth inhibition and G1
arrest in both cell lines, suggesting that this specific effect of
rapamycin contributes significantly to cell growth arrest. Sec-
ond, constitutive activation of the PI3K/Akt pathway frequently
occurs in breast cancer and some of its oncogenic effects are
mediated through the mTOR pathway. This is especially true
in PTEN-deficient tumors or tumors overexpressing Her-2/neu
receptors, which were found to activate this pathway and were
also commonly associated with Skp2 overexpression in differ-
ent cancers [9]. Thus, it seems that rapamycin treatment in
these tumors should be most beneficial. However, not all
breast cancer cells in vitro and tumors in vivo respond equally
to rapamycin and clinically determining the sensitivity to this
drug is of great difficulty. For example, the PI3K/Akt/mTOR
pathway is regulated by PTEN, but not all PTEN-deficient cells
are rapamycin sensitive. Moreover, in our study we did not find
a relationship between the levels of Skp2 expression and sen-
sitivity to rapamycin. Thus, the issue of which subsets of
tumors overexpressing Skp2 may respond the most to
rapamycin is at present unclear. Finally, we show here for the
first time the possible involvement of the APC/C in the regula-
tion of Skp2 abundance in breast cancer cells. We found that
treatment with rapamycin enhanced Skp2 protein degradation
and that this was associated with down-regulation of Emi1, the
inhibitor of the APC/C. Thus, these results suggest that Skp2
deregulation in breast cancer may also be attributed to stabili-
zation of the protein through decreased degradation rate, and
not only from increased transcription.
Figure 4
The effect of rapamycin on Skp2 mRNA levels The effect of rapamycin on Skp2 mRNA levels. T47D cells were treated 
with rapamycin (20 nM) for 8 h and the change in Skp2 mRNA levels 
was determined by real-time RT-PCR. PGK, phosphoglycerate kinase.
Figure 5
The effect of rapamycin on Skp2 degradation The effect of rapamycin on Skp2 degradation. (a) The effect of rapamy-
cin on Skp2 degradation rate. T47D cells were treated with rapamycin 
(20 nM) or DMSO (0.02%) for 24 h followed by treatment with 
cycloheximide (CHX; 100 μg/ml) for the indicated time periods. Levels 
of Skp2 protein levels were determined by western blot analysis. (b) 
The effect of rapamycin on Emi1 protein levels. T47D cells were treated 
with rapamycin (20 nM) and levels of Emi1 were determined by west-
ern blot analysis. Skp1 was used as a loading control.Breast Cancer Research    Vol 8 No 4    Shapira et al.
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Conclusion
The results of the present study provide additional insights into
the mechanisms of action of rapamycin on cell cycle arrest in
breast cancer cells through direct down-regulation of Skp2
expression. Rapamycin inhibited the transcription of Skp2 and
at the same time led to protein destabilization and enhanced
degradation rate. Because Skp2 plays an important role in
tumor progression in breast cancer and clinical outcome,
these results suggest that rapamycin may be of benefit in can-
cers expressing high Skp2 levels.
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